Pseudomonas aeruginosa is a multidrug-resistant nosocomial pathogen. We showed previously that 16 thiostrepton (TS), a gram-positive thiopeptide antibiotic, was imported via pyoverdine receptors and 17 synergized with iron chelator deferasirox (DSX) to inhibit the growth of P. aeruginosa and Acinetobacter 18 baumannii clinical isolates. A small number of P. aeruginosa and A. baumannii isolates were resistant to the 19 combination, prompting us to search for other compounds that could synergize with TS against those 20 strains. From literature surveys we selected 14 compounds reported to have iron-chelating activity, plus 21 one iron analogue, and tested them for synergy with TS. Doxycycline (DOXY), ciclopirox olamine (CO), 22 during infection. To overcome iron limitation, P. aeruginosa produces the iron-scavenging siderophores 37 pyochelin and pyoverdine that bind iron with low and high affinity, respectively (3-5). Pyoverdine and its 38 outer membrane receptors, FpvA and FpvB, are highly expressed in low-iron conditions (3, 6, 7). Pyoverdine 39 has such a high binding affinity (10 32 M -1 ) for iron that it can strip it from transferrin, a mammalian protein 40 responsible for sequestering iron to impede bacterial growth (8-11). RNA-seq data showed that pyoverdine 41 biosynthetic enzymes and uptake are highly upregulated in vivo in response to the iron-deprived 42 environment (7). P. aeruginosa deficient in iron-uptake mechanisms are less able to cause infections 43 compared to their wild-type counterparts (12). 44 45 3 Natural products often exploit iron acquisition pathways to cross the Gram-negative outer membrane. 46 Pyocin S2, produced by P. aeruginosa to kill competing strains, and related toxins are taken up via FpvA (13, 47 
tropolone (TRO), clioquinol (CLI), and gallium nitrate (GN) synergized with TS. Individual compounds were 23 bacteriostatic but the combinations were bactericidal. Our spectrophotometric data and chrome azurol S 24 agar assay confirmed that the chelators potentate TS activity through iron sequestration rather than 25 through their innate antimicrobial activities. A triple combination of TS + DSX + DOXY had the most potent 26 activity against P. aeruginosa and A. baumannii isolates. One P. aeruginosa clinical isolate was resistant to 27 the triple combination, but susceptible to a triple combination containing higher concentrations of CLI, CO, 28 or DOXY. All A. baumannii isolates were susceptible to the triple combinations. Our data reveal a diverse set 29 of compounds with dual activity as antibacterial agents and TS adjuvants, allowing combinations to be 30 tailored for resistant clinical isolates. 31
INTRODUCTION 33
Iron is a critical micronutrient for bacteria, influencing biofilm formation, pathogenicity, and growth (1, 2)., 34
The opportunistic Gram-negative pathogen Pseudomonas aeruginosa has an extensive repertoire of iron 35 acquisition systems that are upregulated during iron-deplete conditions, similar to those encountered 36 14). The sideromycins, which resemble siderophores but have intrinsic antibacterial activity, also exploit 48 iron uptake pathways (15) . Taking advantage of this phenomenon, several groups have created synthetic 49 siderophore-beta-lactam conjugates to target Gram-negative bacteria, using the iron-binding group as a 50 Trojan horse to deliver antibiotics (16-18). One such example is cefiderocol, a siderophore beta-lactam that 51 recently completed Phase III clinical trials. The catechol group of cefiderocol binds iron and the complex is 52 taken up via PiuA, an outer-membrane receptor for iron transport (18, 19) . The compound demonstrated 53 potent activity against Escherichia coli and Klebsiella pneumoniae (19, 21) . Thus, the Trojan horse approach 54 enhances the delivery of antibiotics compared to diffusion alone. 55
56
Our group recently discovered that the thiopeptide antibiotic thiostrepton (TS) hijacks pyoverdine receptors 57 under iron-limited conditions to cross the outer membranes of the World Health Organization's top two 58 critical priority pathogens, P. aeruginosa and Acinetobacter baumannii (22) . TS activity was potentiated in 59 heat-inactivated mouse and human serum, and by FDA-approved iron chelators, deferiprone (DFP) and 60 deferasirox (DSX). However, a small number of P. aeruginosa and A. baumannii strains were resistant to TS-61 chelator combinations, prompting us to look for new compounds that could synergize with TS to inhibit 62 those clinical isolates. 63
64
With the aim of finding compounds that could synergize with TS in iron-limiting conditions, we performed a 65 literature search to identify bioactive iron chelators. We selected 14 putative iron-binding compounds as 66 well as gallium, an iron analogue. Five compounds synergized with TS and had activity against P. aeruginosa 67 and A. baumannii clinical isolates. Each compound was bacteriostatic against P. aeruginosa PA14; however, 68 the addition of TS made the combination bactericidal. Growth of one highly-resistant P. aeruginosa clinical 69 isolate was inhibited with higher concentrations of three of the compounds in combination with TS+DSX. 70
These data identify a set of molecules of diverse structure and biological activity that synergize with TS, 71 providing the ability to tailor combinations for resistant strains. 72
73

RESULTS 74
Iron-binding antibiotics form coloured complexes 75
We first screened a panel of common antibiotics for potential iron-chelating activity using a qualitative 76 assay, monitoring change in colour upon addition of FeCl 3 . Binding of transition metals results in formation 77 4 of coloured complexes that absorb in the visible wavelengths of light, detectable by spectroscopy and by 78 eye (23-25). The panel consisted of 22 antibiotics from the aminoglycoside, fluoroquinolone, beta-lactam, 79 and tetracycline classes (Fig. 1) . Iron chelators DFP and DSX served as positive controls, turning dark 80 red/violet upon addition of ferric iron at a final concentration of 10 µM. The tetracyclines -doxycycline 81 (DOXY), tetracycline, and minocycline -exhibited similar colour changes. The fluoroquinolones -82 ciprofloxacin, ofloxacin, and pipemedic acid -formed orange complexes; however, the intensity of the 83 colour change was weaker compared to the tetracyclines, DFP, and DSX. A number of beta-lactams showed 84 colour changes ranging from a brown-orange to red-orange. Ceftriaxone was the only beta-lactam that 85 turned red in the presence of ferric iron. Trimethoprim turned golden-yellow. 86 87
Binding of ferric iron shifts absorption spectra 88
To verify spectral shifts for compounds that changed colour upon addition of ferric iron, a 96-well 89 spectrophotometric assay was performed, with final concentrations of antibiotic and FeCl 3 of 300 µM each. 90
The absorption spectra were scanned from 300 -700 nm. The spectra of ciprofloxacin (CIP), pipemedic acid, 91 ofloxacin, tetracycline, minocycline, DOXY, DSX and DFP shifted after the addition of FeCl 3 (Fig. 2) , 92 confirming the results of the qualitative assay. Chloramphenicol and ampicillin served as negative controls. 93
The spectrum for ceftriaxone did not change at the concentrations tested, suggesting that the changes in 94 color observed for beta-lactams were likely due to concentration effects. 95 96
Identification of other compounds that chelate iron 97
To expand our panel of potential chelators beyond known antibiotics, we searched the literature for 98 bioactive compounds that were reported to have iron-chelating activity. We identified 14 compounds 99 (Table 1) plus gallium nitrate (GN). Gallium is an iron analogue that inhibits siderophore production, iron 100 uptake, and the activity of enzymes that use iron (26). The spectrophotometric assay was repeated for all 101 compounds listed in Table 1 except for clioquinol (CLI). CLI was identified in our previous screen as a P. 102 aeruginosa growth inhibitor (22) but precipitated at concentrations above 8 µg/mL. Ciclopirox olamine (CO) 103 and tropolone (TRO) showed shifts in their absorption spectra (Fig. 2) . A chrome azurol S (CAS) assay was 104 also used to detect iron binding through de-colourization of the blue agar, indicating removal of Fe 3+ from 105 the CAS-HDTMA complex (Fig. S1) . DSX, TRO, and CO showed the greatest decolourization, and thus the 106 highest relative affinity for iron. Interestingly, DOXY showed a marked colour shift in the presence of Fe 3+ 107 ( Fig. 2) but minimally decolourized CAS agar. 108 109
Numerous iron chelators synergize with TS 110
Based on their ability to bind iron, each compound from Table 1 , as well as DOXY and CIP, were assessed for 111 synergy with TS using checkerboard assays. DOXY, CO, CLI, TRO, and GN all synergized with TS ( Fig. 3) , as 112 IC 50 isobolograms showed that all combinations were below the line of additivity. Combination indices (CIs) 113 were less than 1 (Fig. 3E) . Based on the checkerboards, isobolograms, and CI values, CO and CLI 114 demonstrated the most potent synergy with TS while GN had the weakest. Attempts to combine GN with 115 DSX or CO resulted in antagonism, likely due to the chelators binding Ga 3+ (Fig. S2) . 116 117
Each compound potentiates TS activity 118
We previously showed that iron chelation potentiated the effects of TS, as DSX alone had no anti-119
Pseudomonas activity (22). CLI, TRO, DOXY, and CO can inhibit P. aeruginosa growth, suggesting that the 120 innate activity of the compounds could be partly responsible for synergy with TS. Thus, we considered four 121 potential mechanisms of synergy. 1) TS potentiates the activity of each compound through an unknown 122 mechanism.
2) The compound potentiates TS activity by chelating calcium and magnesium and increasing 123 outer membrane permeability or 3) by chelating iron and increasing TS uptake. In all these cases, the 124 synergy is unidirectional. 4) TS and the compound potentiate one another through an unknown mechanism. 125 126 Our data suggest that the synergy between TS and each compound is due to their iron chelation capacity 127 rather than membrane permeabilization. First, to determine if DOXY could increase outer membrane 128 permeability, vancomycin (VAN) and DOXY combinations were tested against PA14 alone or in the presence 129 of Ca 2+ , Mg 2+ or Fe 3+ (Fig. S3 ). VAN was selected because it is similar to TS in size but unlike TS, its activity is 130 unrelated to iron availability. VAN has a high minimal inhibitory concentration (MIC) against P. aeruginosa 131 due to limited uptake across the outer membrane. If a compound increases membrane permeability, we 132 expect synergy with VAN. In our checkerboard assays, no synergy was identified for VAN + DOXY, VAN + CLI, 133 VAN + CO, or VAN + TRO. Further, addition of 100 µM Mg 2+ or Ca 2+ had no effect on the checkerboard 134 profiles compared to control. In contrast, addition of 100 µM Fe 3+ abrogated the inhibitory activity of CLI, 135 TRO, and CO, confirming that iron chelation is a critical part of the mechanism by which those compounds 136 impede growth. Lack of synergy between VAN + DOXY also suggested lack of membrane permeabilization. 137
The addition of 100 µM Mg 2+ had no effect on the checkerboard whereas the addition of Fe 3+ and Ca 2+ had a 138 negligible effect. This is reflective of the relatively weak ability of DOXY to compete for iron in the CAS assay 139 To test the hypothesis that the compounds potentiate TS activity, rather than the other way around, 3D 142 checkerboard assays were performed using PA14. The surface area of each checkerboard was expressed as 143 % of control and graphed against the concentration of the third compound ( Fig. S4) . Individual MIC assays 144 for each compound were performed and the results graphed as % of control on the same y-axis on a log 10 145 scale. Significant differences between the two datasets would indicate that the TS + DSX combination 146 potentiates the activity of the test compound. To account for potential antagonism between test 147 compounds and DSX, 2D checkerboard assays were conducted (Fig. S5) . DSX + TRO and DSX + CO were 148 indifferent. CLI antagonized with DSX at the MIC; however, we could not test concentrations of CLI greater 149 than 8 µg/mL due to its poor solubility. DSX was additive with DOXY. We saw no significant differences 150 between the activity of the chelators alone or in combination with TS and DSX, except for with CLI ( Fig.  151   4ABCD) . CLI antagonized DSX at the highest concentration; however, growth was still below 20% of control 152 ( Fig. 4C) , which we previously established as equivalent to the MIC in the growth medium used for this work 153 (22). When the data were plotted against TS concentration ( Fig. 4E ), significant differences for the 154 combinations were apparent at 2 and 4 µg/mL TS compared to TS alone, indicating that the compounds and 155 DSX potentiate TS activity. These data suggest that the synergy between the chelators and TS is 156 unidirectional. 157 158 TS combinations are bactericidal and effective against clinical isolates 159 TS, CO, CLI, DOXY, and TRO alone were bacteriostatic; however, when combined with TS, the combinations 160 were bactericidal (Fig. S6) . This improved activity prompted us to test the combinations against clinical 161 isolates. Double (TS + compound) and triple combinations (TS + DSX + compound) were tested against same 162 panels of P. aeruginosa and A. baumannii clinical isolates we previously assayed for susceptibility to TS + 163 DSX ( Fig. 5) (22) . GN was omitted due to its weak synergy with TS against PA14 and antagonism with iron 164 chelators ( Fig. S2) . TS and DSX were used at 8.3 µg/mL (5 µM) and 32 µg/mL as before, while the other 165 compounds were added at 1/8 th the MIC of PA14, corresponding to DOXY, CO, TRO, and CLI concentrations 166 of 1 µg/mL, 2 µg/mL, 4 µg/mL, and 1 µg/mL, respectively. 167
168
Of the double combinations, TS + DSX was the most potent against P. aeruginosa (Fig. 5A) , consistent with 169 our checkerboard assays. Interestingly, TS + DOXY and TS + CO had similar potency despite differences in 170 their CI values (Fig. 3) . TS + TRO was the least potent of the double combinations. TS + CLI potency was 171 similar to TS + DSX, and this combination reduced growth of our most resistant clinical isolate, C0379, while 172 TS + DSX did not. TS synergized with CLI to inhibit C0379 although a higher concentration (8 µg/mL) of CLI 7 was required ( Fig. 6) . Of the triple combinations, TS + DSX + DOXY was the most potent, with only C0379 174 showing resistance. We previously reported that C0379 has a partial deletion of fpvB, encoding a 175 pyoverdine receptor (22). However, triple combinations with higher concentrations of DOXY and CO could 176 inhibit its growth (Fig. 6AC) . C0379 growth was also inhibited by TS + CLI or TS + DSX + CLI, if CLI was used at 177 8 µg/mL. CLI alone did not reduce growth below MIC and there was no antagonism between DSX and CLI 178 with C0379 compared to PA14 (Fig. 6B) . C0379 was also less susceptible to TRO compared to PA14 (Fig. 6D) . assays. The CAS assay, which is used to detect siderophore production, not only indicates whether a 206 compound can bind iron, but also if it has a stronger affinity for the metal than the CAS-HDTMA complex. 207
This allowed us to compare the relative binding affinities of various compounds based on the extent of 208 decolourization. This method is limited by compound solubility, as seen with CLI ( Fig. S1) . 209 210 None of the natural phytochelators from plants that we tested -including baicalin, ferulic acid, sodium 211 phytate, 2,3,5,6-tetrametylpyrazine, curcumin, epigallocatechin gallate, and phloretin (Table 1) -synergized 212 with TS. P. aeruginosa can act as a plant pathogen and may have evolved to outcompete or even take up 213 phytochelators (30-33). The compounds that synergized with TS are all synthetic and the extent of synergy 214 correlated with their ability to strip iron from CAS-Fe 3+ -HDTMA complexes ( Fig. 3 and Fig. S1 ). Iron chelators 215 compete with siderophores and reduce iron availability, resulting in increased pyoverdine receptor 216 expression and susceptibility to TS (34). Weaker chelators such as DOXY and CIP showed little or no synergy 217 with TS whereas strong chelators like CO and TRO exhibited greater synergy. 218
219
The GN data demonstrate that synergy with TS can occur via routes other than iron chelation. Ga 3+ 220 represses pyoverdine production and forms complexes with pyoverdine that prevents iron binding (35, 36). 221 TS activity could be weakly potentiated because of reduced competition for pyoverdine receptors if 222 siderophore production decreases upon GN treatment. These data show that disrupting iron acquisition 223 may be another avenue for novel TS combinations. GN in triple combinations with TS + chelator has limited 224 utility because iron chelators bind Ga 3+ (Fig. S2 ). However, one study showed that LK11, a compound that 225 inhibits pyoverdine function directly, sensitized cells to CO to the same extent as a pyoverdine null mutant 226 (37). Our previous work showed that a PA14 pvdA transposon mutant was more susceptible to TS compared 227 to the wild type, which suggests that pyoverdine biosynthesis inhibitors could be useful TS adjuvants (22) . Bacterial strains, compounds, and culture conditions 248 P. aeruginosa PA14 was used for checkerboard assays as previously described (22). All clinical isolates were 249 from the Wright Clinical Collection as described previously. Bacteria overnight cultures were grown in 250 lysogeny broth (LB) and subcultured in 10:90 medium (10% LB, 90% phosphate buffered saline (PBS)). All 251 growth assays were done using 10:90 and grown for 16h at 37°C and 200 rpm. Compounds from Table 1  252 were from AK Scientific, Sigma, and Cayman Chemicals. TS and DSX were from Cayman Chemicals and AK 253 Scientific respectively. Compounds were stored at -20°C. Stock solutions were stored at -20°C until use 254 except for the tetracyclines, which were made fresh due to precipitation at -20°C. 150μL. The plate was incubated at room temperature for one hour and absorption spectra from 300 nm to 261 700 nm was read in 2nm increments (Multiskan Go -Thermo Fisher Scientific). 262
263
CAS assay 264
CAS agar plates were prepared as described previously (22). Compounds were standardized to 2 mg/mL and 265 10 µL of each was spotted onto the plate. Plates were incubated at room temperature for 1 h, then 266 photographed. Three replicates were conducted and the image of a representative plate was presented. 267 268
Dose response and checkerboard assays 269
Dose response and checkerboard assays were conducted as described previously (22) . Briefly, overnight 270 cultures were grown in LB for 16 h, 37°C, 200 rpm then subcultured (1:500 dilution) into 10:90 for 6 h. 271
Subcultures were standardized to OD 600 of 0.10 and diluted 1:500 in fresh 10:90 before use. Isolates from the Wright Clinical Collection were grown and tested as described previously (22) . Briefly, 298 clinical isolates were inoculated from glycerol stocks stored at -80°C into Nunc 96-well plates and grown 299 overnight at 37°C, for 16 h with shaking in LB (200 rpm). Overnights were subcultured (1:25) into fresh 300 11 10:90 medium and grown for 2 h under the same growth conditions. Subcultures were diluted 1:75 in fresh 301 10:90. Compounds were diluted 1:75 to obtain the final concentration. DOXY and CLI were added at a final 302 concentration of 1 µg/mL, CO was used at 2 µg/mL, TRO was used at 4 µg/mL, TS was used at 8.3 µg/mL, 303 and DSX was used at 32 µg/mL. Vehicle and sterility controls were included. Plates were incubated 304 overnight with the same conditions. The OD 600 was read (Multiscan Go -Thermo Fisher Scientific), analyzed 305 using Excel, and the data plotted using Prism (GraphPad). 306 307 
